Hartmut Goldschmidt
Hartmut Goldschmidt
Universitätsklinikum Heidelberg
Verified email at - Homepage
Cited by
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, ...
New England journal of medicine 352 (24), 2487-2498, 2005
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ...
Journal of clinical oncology 33 (26), 2863, 2015
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ...
New England Journal of Medicine 375 (14), 1319-1331, 2016
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ...
New England Journal of Medicine 384 (8), 705-716, 2021
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial
P Sonneveld, IGH Schmidt-Wolf, B van der Holt, L El Jarari, U Bertsch, ...
Journal of clinical oncology 30 (24), 2946-2955, 2012
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label …
J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ...
The lancet oncology 14 (11), 1055-1066, 2013
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label …
MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ...
The Lancet Oncology 17 (1), 27-38, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ...
Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ...
New England Journal of Medicine 380 (22), 2104-2115, 2019
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Moreau, J San Miguel, P Sonneveld, MV Mateos, E Zamagni, ...
Annals of oncology 28, iv52-iv61, 2017
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
PG Richardson, P Sonneveld, M Schuster, D Irwin, E Stadtmauer, T Facon, ...
Blood, The Journal of the American Society of Hematology 110 (10), 3557-3560, 2007
IMWG consensus on risk stratification in multiple myeloma
WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, ...
Leukemia 28 (2), 269-277, 2014
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
R Haas, R Mohle, S Fruhauf, H Goldschmidt, B Witt, M Flentje, ...
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
MA Dimopoulos, P Moreau, E Terpos, MV Mateos, S Zweegman, G Cook, ...
Annals of Oncology 32 (3), 309-322, 2021
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
M Dimopoulos, R Kyle, JP Fermand, SV Rajkumar, J San Miguel, ...
Blood, The Journal of the American Society of Hematology 117 (18), 4701-4705, 2011
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ...
The lancet oncology 18 (4), e206-e217, 2017
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
K Neben, HM Lokhorst, A Jauch, U Bertsch, T Hielscher, B van der Holt, ...
Blood, The Journal of the American Society of Hematology 119 (4), 940-948, 2012
The system can't perform the operation now. Try again later.
Articles 1–20